Progesterone Fatty Acid Carrier Solubility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current formulations of hydrophobic drugs like progesterone, particularly those suspended in oils, exhibit high interpatient and intrapatient variability and low bioavailability, along with adverse reactions due to oil-based carriers.
Innovation Solution
Formulations containing progesterone dissolved in a fatty acid-based carrier composition with high concentrations of fatty acids and organic acids, which enhance bioavailability and stability, allowing for higher effective doses without oil-based carriers that cause adverse reactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If progesterone is suspended in oil-based carriers (e.g., peanut oil), then the formulation can be administered orally, but bioavailability is low and interpatient/intrapatient variability is high
Solution Approach 1:
The patent changes the physical-chemical parameters of the carrier system by replacing oil-based carriers with fatty acid-based carriers (e.g., medium-chain fatty acids like caprylic acid, capric acid). This parameter change increases progesterone solubility and dissolution rate, thereby improving bioavailability while maintaining oral administration feasibility
Solution Approach 2:
The patent uses composite carrier systems comprising fatty acids combined with co-solvents (e.g., ethanol, propylene glycol) and surfactants. This composite approach creates a synergistic effect that enhances progesterone solubility, stability, and dissolution properties, resolving the contradiction between oral feasibility and bioavailability
2Quantity of substance
If progesterone concentration is increased in the formulation, then higher effective doses can be achieved, but solubility limitations prevent adequate dissolution
Solution Approach 1:
The patent changes the solvent parameters by using fatty acid-based carriers with specific solubility characteristics for progesterone. This allows formulation of high-concentration progesterone solutions (e.g., 20-50% w/w) that remain stable and fully soluble, overcoming the solubility limitations of traditional oil-based carriers
Solution Approach 2:
The patent introduces fatty acids as intermediary substances that mediate between progesterone and the aqueous environment. These fatty acids act as solubilizing agents that enable high progesterone concentrations while maintaining solution stability and preventing precipitation
3Ease of manufacture
If traditional oil-based carriers are used, then formulation is simple, but adverse reactions occur due to allergic responses
Solution Approach 1:
The patent extracts and removes the problematic oil-based carrier component from the formulation, replacing it with fatty acid-based carriers. This elimination of the allergenic substance (peanut oil, soybean oil, etc.) while maintaining the carrier's essential functions resolves the contradiction between formulation simplicity and avoidance of allergic reactions
Solution Approach 2:
The patent employs fatty acids that can be rapidly metabolized and eliminated by the body, replacing persistent oil-based carriers. These fatty acid carriers provide the necessary formulation functions but are quickly processed by the body, reducing the risk of cumulative allergic responses and improving safety
4Speed
If progesterone is micronized and suspended in oil, then oral administration is possible, but dissolution rate is slow and absorption is poor
Solution Approach 1:
The patent changes the dissolution parameters by using fatty acid-based carriers that provide immediate solubility for progesterone upon contact with gastrointestinal fluids. This eliminates the slow dissolution step required for micronized suspensions in oil, achieving rapid dissolution and fast absorption, thereby resolving the contradiction between dissolution rate and absorption efficiency
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The fatty acid-based formulations demonstrate improved dissolution in aqueous media and increased bioavailability, reducing variability and minimizing allergic reactions, with progesterone releasing significantly higher amounts over time compared to traditional oil-based formulations.
Implementation Method 1
progesterone dissolved in a fatty acid-based carrier composition with high concentrations of fatty acids and organic acids
Implementation Method 2
The fatty acid-based formulations demonstrate improved dissolution in aqueous media and increased bioavailability, with progesterone releasing significantly higher amounts over time
Data Source
AI summary
Fill materials for hydrophobic drugs, such as progesterone, and methods of making and using thereof are described herein. The fill material contains the hydrophobic drug dissolved in one or more fatty acids. The concentration of the hydrophobic drug is typically from about 7% to about 50% by weight of the fill material. The concentration of the one or more fatty acids is from about 60% to about 95% by weight of the carrier. The formulation also contains an organic acid and one or both of one or more pharmaceutically acceptable alcohols and one or more pharmaceutically acceptable mono-, di-, or triesters of medium or long chain fatty acids. The fill material can be encapsulated in a hard or soft capsule. The formulations described herein have a higher dissolution rate and faster onset of dissolution compared to micronized progesterone suspended in an oil and thus should have increased bioavailability in vivo.